Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress…
Posted: October 28, 2020 at 3:54 am
NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will be presenting a poster during the 29th European Academy of Dermatology and Venereology (EADV) Congress being held virtually October 28 – November 1, 2020. The presentation will be posted onto Akari’s website.
See the original post here:
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress...
Posted in Global News Feed
Comments Off on Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress…
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Posted: October 28, 2020 at 3:54 am
GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX?CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix?M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) meeting.
More here:
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Posted in Global News Feed
Comments Off on Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results
Posted: October 28, 2020 at 3:54 am
California cannabis leader to host conference call on November 10, 2020 California cannabis leader to host conference call on November 10, 2020
Continue reading here:
Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results
Posted in Global News Feed
Comments Off on Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results
Galapagos’ R&D Roundtable showcases Toledo program
Posted: October 28, 2020 at 3:54 am
Mechelen, Belgium; 27 October 2020, 16.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) unveils the Toledo target family as a series of salt-inducible kinase inhibitors. Toledo exhibits a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. Today, Galapagos also presents new preclinical and healthy volunteer data, and details its broad program to discover and develop multiple series of Toledo compounds with different selectivity profiles, aimed at treating a broad range of autoimmune conditions with important unmet medical need.
Visit link:
Galapagos’ R&D Roundtable showcases Toledo program
Posted in Global News Feed
Comments Off on Galapagos’ R&D Roundtable showcases Toledo program
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
Posted: October 28, 2020 at 3:54 am
NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company’s American Depositary Receipts (“ADRs”).
Go here to see the original:
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
Posted in Global News Feed
Comments Off on Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
Sanofi: Information concerning the total number of voting rights and shares – September 2020
Posted: October 28, 2020 at 3:54 am
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
Read the original here:
Sanofi: Information concerning the total number of voting rights and shares - September 2020
Posted in Global News Feed
Comments Off on Sanofi: Information concerning the total number of voting rights and shares – September 2020
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
Posted: October 28, 2020 at 3:54 am
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its third quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks.
Read more here:
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
Posted in Global News Feed
Comments Off on Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed…
Posted: October 28, 2020 at 3:54 am
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting
Posted in Global News Feed
Comments Off on Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed…
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Posted: October 28, 2020 at 3:54 am
SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets close on Thursday November 12, 2020.
Original post:
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Posted in Global News Feed
Comments Off on Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
Posted: October 28, 2020 at 3:54 am
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market.
See the original post:
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
Posted in Global News Feed
Comments Off on Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020